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Objective: This article reports the intermediate-term (24-month) outcomes of a prospective multicenter trial designed to
evaluate the Zenith Fenestrated AAA Endovascular Graft (Cook Medical, Bloomington, Ind) for treating juxtarenal
abdominal aortic aneurysms with short proximal necks. The study goals were to evaluate the safety and preliminary
effectiveness of the device and refine patient selection criteria.
Methods: Five centers in the United States enrolled 30 patients with juxtarenal aortic aneurysms with >50-mm diameter
and short proximal necks. Devices were custom-designed for each patient based on measurements from reconstructed
computed tomography (CT) data. Follow-up studies included physical examinations, laboratory studies, CT imaging,
mesenteric-renal duplex ultrasound imaging, and abdominal flat plate radiographs at hospital discharge, at 1, 6, and 12
months, and yearly thereafter up to 5 years.
Results: During a 1-year period, 30 patients (80% men; mean age, 75 years) with a mean aneurysm size of 61.4 mm were
enrolled. In these 30 patients, 77 visceral vessels were accommodated by fenestrations located within the sealing segment
of the grafts. The most common design accommodated two renal arteries and the superior mesenteric artery (66.7%). All
prostheses were implanted successfully. No visceral arteries were lost. Of the 30 patients treated, 27 were available for
12-month follow-up and 23 were available for 24-month follow-up. No aneurysm-related deaths, aneurysm ruptures, or
conversions were observed through 24 months of follow-up. No type I or type III endoleaks were observed. Type II
endoleaks were noted in six (26.1%) at 12 months and four (20.0%) at 24 months. No patients had aneurysm growth>5
mm. Aneurysm size decreased in 16 of 23 (69.6%) and was stable in the remaining patients at 24 months. Eight patients
experienced a renal event (4 renal artery stenoses, 2 renal artery occlusions, and 2 renal infarcts). Five underwent
secondary interventions. No renal failure developed requiring dialysis.
Conclusions: The intermediate-term (24-month) results of the 30 patients in this multicenter study are concordant with
previous single-center studies and support the concept that placement of fenestrated endovascular grafts is safe and effective at
centers with experience in endovascular repair and renal/mesenteric stent placement. (J Vasc Surg 2009;50:730-7.)Unfavorable anatomy of the proximal aortic neck of an
infrarenal abdominal aortic aneurysm (AAA) is the most
common factor (up to 40% of patients) precluding patients
from an endovascular treatment option.1,2 Multiple studies
of conventional commercial aortic endografts3-5 have dem-
onstrated that short or compromised proximal aortic necks
can lead to inadequate proximal seal by the graft and are
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730associated with higher incidences of proximal endoleak,
device migration, and aneurysm rupture. These results have
led to a well-accepted anatomic requirement for a proximal
neck length of 15 mm for most commercially available
endografts in the United States.
If such exclusion criteria could be addressed by a mod-
ified endovascular approach, up to 80% of infrarenal aneu-
rysms could be managed in a minimally invasive fashion.2
Endovascular grafts with fenestrations, which are openings
within the graft fabric to accommodate visceral arteries,
have been developed to improve the proximal seal by
incorporating segments of the visceral arteries into the
proximal sealing zone.
Initial reports have demonstrated the technical feasibil-
ity of using fenestrated devices and documented short-term
to intermediate-term safety and effectiveness.6-12 How-
ever, the absence of multicenter trial data has often raised
the question whether these devices can be made more
widely available. This article reports the results of first
prospective multicenter trial intended to assess the safety
and effectiveness of the Zenith fenestrated device (Cook
Medical, Bloomington, Ind).
neral Hospital as a result of Hurricane Katrina in 2005.
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Six centers (Table I) with experience in conventional
endovascular grafting and familiarity with the interven-
tional treatment of renal and mesenteric occlusive disease
participated in patient enrollment of this study. Five centers
enrolled 30 patients between January 2005 and January
2006. Informed consent, approved by the respective insti-
tutions’ Institutional Review Boards, was obtained for all
individuals treated.
Preoperative assessment anddevice sizing. Preoperative
high-resolution computed tomography (CT) scans for all
patients, and angiography obtained at the physician’s dis-
cretion, were used to determine if the aneurysm morphol-
ogy was unsuitable for traditional infrarenal endovascular
grafts yet within the anatomic guidelines (Table II) for
repair with the Zenith fenestrated device.
Customized devices for each patient (Fig 1) were de-
signed according to multiplanar reconstruction and center-
line of flow calculations derived from CT scans. Diameters
and lengths of the aorta and iliac arteries, and visceral vessel
morphology were used to denote the relative positions of
visceral vessels intended to be incorporated within the
sealing zone of the fenestrated device in a manner similar to
prior publications.1 Small, large, or scalloped fenestrations
were included as options for the device design. Device
designs proposed by the implanting physicians were re-
viewed by at least one of two centers with prior experience
with device planning (William A. Cook Australia and
Cleveland Clinic). The following guidelines were used for
device design:
● Adequate seal must be achieved after placement of the
proximal sealing stent within a segment of aorta that
radiographically appears relatively healthy; for exam-
ple, parallel walls, consistent diameter, and free of
luminal debris.
● The target vessel to be stented must have adequate
length without aneurysmal involvement.
● The proximal fenestrated component must terminate
approximately 20 to 30 mm above the aortic bifurca-
tion.
● The modular distal bifurcated component must have a
Table I. Participating centers in the Cook Zenith Fenestr
Institution Locatio
Cleveland Clinic Foundation Cleveland, O
Massachusetts General Hospital Boston, Ma
Ochsner Clinic New Orleans
University of California, San Francisco/VA San Francisco
University of Pittsburgh Medical Center Pittsburgh, P
Hospital of the University of Pennsylvania Philadelphia,
Total
aThis center enrolled one patient who later transferred to Massachusetts Geminimum of two stents (50-mm) of overlap with theTable II. Inclusion and exclusion criteria for the Zenith
Fenestrated AAA Endovascular Graft trial
Inclusion criteria
● Aortic or aortoiliac aneurysm with diameter 5 cm
● Aortic or aortoiliac aneurysm with a history of growth 0.5
cm/y, or clinical indication for AAA repair
Exclusion criteria
General exclusion criteria
● Age 18 years
● Life expectancy 2 years
● Pregnant or breastfeeding
● Unwilling to comply with the follow-up schedule
● Inability or refusal to give informed consent
Medical exclusion criteria
● Baseline creatinine 2.0 mg/dL
● Cultural objection to receipt of blood or blood products
● Allergic to stainless steel or polyester
● Anaphylactic reaction to contrast material
● Leaking/ruptured or symptomatic aneurysm
● Uncorrectable coagulopathy
● Previous stent in any renal or visceral artery to be accommo-
dated with a small fenestration
Anatomic exclusion criteria
● Significant occlusive disease, tortuosity, or calcification
● Proximal neck 4 mm, or 15 mm in length unless otherwise
compromised to preclude seal
● Proximal neck, measured outer wall to outer wall on a sec-
tional CT image 31 mm or 19 mm in diameter
● Proximal neck angulated 45° relative to the long axis of the
aneurysm
● Immediate suprarenal neck angulated 45° relative to the im-
mediate infrarenal neck
● Proximal neck diameter change over the length of the proxi-
mal seal zone 4 mm
● Proximal seal site with circumferential thrombus/atheroma
above the renal arteries
● Iliac artery diameter, measured inner wall to inner wall on a
sectional CT image 7.5 mm at any point along access length
(before deployment)
● Ipsilateral iliac artery fixation site diameter, measured inner
wall to inner wall on a sectional CT image 9.0 mm before
deployment
● Iliac artery diameter, measured outer wall to outer wall on a
sectional CT image 21 mm at distal fixation site
● Iliac artery distal fixation site 30 mm in length
● Inability to maintain at least one patent hypogastric artery
● Renal artery stenosis 50%
● Nonbifurcated segment of any artery to be stented 15 mm
in length
● Unsuitable arterial anatomyated AAA Endovascular Graft trial
n Principal investigator
Patients
enrolled, No.
hio Sean Lyden, MD 8
Christopher J. Kwolek, MD 6
, La W. Charles Sternbergh III, MD 0a
, Calif Darren Schneider, MD 7
a Michel Makaroun, MD 6
Pa Ronald Fairman, MD 3
30AAA, Abdominal aortic aneurysm; CT, computed tomography.
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overlap recommended.
Device implantation. A proctor physician who had
experience with the fenestrated endograft was present for
all cases in this study. Fundamental aspects of the deploy-
ment technique will be summarized subsequently and are
described in detail in previously published reports.9,10 In
brief, patients were given anticoagulation therapy and bi-
lateral femoral access was obtained. A stiff guidewire was
introduced on the side intended for delivery of the proximal
fenestrated component, and a large diameter, valved sheath
(20F to 22F Check-Flo, Cook Medical) was inserted from
the contralateral side for access to fenestrations. The prox-
imal fenestrated component was introduced and oriented
by visualizing the radiopaque gold markers on the anterior
and posterior aspects of the graft component and around
each fenestration.
The proximal component was partially deployed, and
the fenestrations were aligned with the corresponding vis-
ceral vessels. Sheaths or guiding catheters were then in-
serted through the contralateral access sheath into all fen-
estrations and the respective vessels that were to be stented.
The constraining wire was removed to fully expand the
graft, and the top cap was deployed to release the uncov-
ered barbed fixation stent.
The study protocol required stent placement in all visceral
vessels accommodated by small fenestrations, whereas stent
placement through large fenestrations or scallops was per-
formed at the discretion of the implanting physician. Stents
were deployed such that most of the stent was anchored
within the visceral artery and approximately 2 to 4 mm of the
stent extended into the aorta. Flaring of the proximal (aortic)
end of the stents was achieved with a 10-mm-diameter balloon.
The distal bifurcated component was deployed, ensur-
ing adequate overlap with the proximal fenestrated compo-
nent. The leg component was then deployed in a manner
similar to conventional Zenith AAA endovascular grafts. A
large diameter balloon (eg, CODA Balloon, Cook Medi-
cal) was inflated at the overlap joints and distal sealing
regions of the device to assure optimal sealing between the
graft and the aorta. An angiogram was recorded after the
Fig 1. This photograph of the Zenith Fenestrated AAA Endovas-
cular Graft shows the components of the endograft, as well as the
scallop and small fenestrations.procedure to assess for endoleak and graft patency.Patient follow-up. CT scans, visceral duplex ultra-
sound imaging, abdominal radiographs, physical examina-
tions, and laboratory studies were obtained before dis-
charge, at 1, 6, and 12 months, and yearly thereafter up to
5 years. Imaging studies were evaluated by the investigative
sites and the core laboratory. Data presented here reflect
only the results from the core laboratory analysis.
Data analysis. Data were managed by MED Institute
Inc. All statistical analyses were performed using SAS 9.1
software (SAS Institute, Cary, NC). Specific endovascular
outcomes, including technical success, clinical success, an-
eurysm size change, endoleaks, migration, device integrity,
and death were analyzed in accordance with the reporting
standards for endovascular aortic aneurysm repair.13 Ad-
verse events were defined and analyzed in a manner similar
to previous Zenith AAA studies,14,15 and the Kaplan-Meier
method was used to assess freedom from major adverse
events. Renal events were defined as a serum creatinine rise
by30% from baseline and to2 mg/dL on two or more
follow-up tests, or detection of new renal pathology (ste-
nosis, occlusion, dissection, or infarct) involving renal ar-
teries accommodated by the fenestrations.
RESULTS
Preprocedural patient characteristics. The stringent
anatomic exclusion criteria resulted in the rejection of 19
screened candidates from this study after detailed film
review. Causes of the rejections are presented in Table III
(online only). This study included 30 patients (24 men and
Table IV. Pre-existing risk factorsa and smoking status
Factor
No. (%)
N  30
Cardiovascular
Prior myocardial infarction 8 (26.7)
Prior diagnosis of CHF 3 (10.0)
Prior diagnosis of CAD 15 (50.0)
Prior diagnosis of arrhythmia 14 (46.7)
Hypertension 26 (86.7)
Vascular
Thromboembolic event 5 (16.7)
Peripheral vascular disease 7 (23.3)
Family history of aneurysmal disease 4 (13.3)
Pulmonary
COPD 9 (30.0)
Renal
Failure requiring dialysis 0 (0)
Insufficiency 2 (6.7)
Diabetes 7 (23.3)
Neurologic
Prior diagnosis of CVD 5 (16.7)
Previous endarterectomy 1 (3.3)
Smoking
Current 8 (26.7)
Quit 19 (63.3)
Never 3 (10.0)
CAD, Coronary artery disease; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; CVD, cerebrovascular disease.
aPatients may have presented with more than one comorbid condition.6 women), with a mean age of 75 years (range, 59-86
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was common (Table IV). Only two patients (6.7%) had
documented pre-existing renal insufficiency.
The mean maximum aneurysm diameter was 61.4 mm
(SD, 9.7 mm; range, 48.8-88.0 mm). All patients had short
(15 mm) proximal necks (9.2 [SD, 2.9]; range, 2.4-14.4
mm). The shape of the sealing zone was considered parallel
in 63.3%, funnel in 16.7%, inverted funnel in 6.7%, or
irregular in 13.3%. The mean angle between the suprarenal
and perirenal aorta was 15.8° (SD, 9.3°; range, 2°-40°),
and the mean angle between the perirenal and infrarenal
aorta was 32.4° (SD, 13.8°; range, 7°-57°).
Device design. In this study, 77 visceral vessels were
accommodated by fenestrations (Table V), including 47
renal arteries accommodated by small fenestrations, and 10
renal arteries and 20 superior mesenteric arteries (SMAs)
accommodated by scallop fenestrations. None of the de-
vices incorporated the celiac artery or an accessory renal
artery into the repair; however, accessory renal arteries were
covered at the discretion of the implanting physician, pro-
vided the primary renal arteries carried most of the renal
flow. The most common proximal fenestrated design in-
cluded a scallop for the SMA and two small fenestrations for
the main renal arteries (66.7%).
Procedural data. Median procedure time was 234
minutes (range, 170-554 minutes). Average blood loss was
601 mL (range, 50-2400 mL), and seven patients required
replacement blood products. Themean stay in the intensive
care unit was 0.8 days (range, 0-6 days), and overall length
of hospital stay averaged 3.7 days (range, 1-8 days). Pa-
tients required an average of 1.4 days (range, 0-5 days)
from the procedure to resume a regular diet and 1.4 days
(range, 0-7 days) to ambulation.
During the procedure, uncovered metal stents were
placed in 54 renal arteries (47 small fenestrations, 7 scal-
lops). No stents were placed in SMAs. Adjunctive proce-
dures included placement of an iliac conduit in 1 patient,
iliac angioplasty for device passage in 1, iliac stent place-
ment in 2, angioplasty within a kinked iliac limb in 1,
femoral endarterectomy in 1, and thromboendarterec-
tomy in 1.
Procedural angiography resulted in 12 patients being
diagnosed with endoleaks: 3 with type Ia, 1 with combined
type Ia and type III, 4 with type III between the proximal
Table V. Configuration of the proximal fenestrated
component
Configuration
No. (%)
(N  30)
1 SMA scallop  2 RA small fenestrations 20 (66.7)
2 RA small fenestrations 1 (3.3)
1 main RA scallop  1 main RA small fenestration 5 (16.7)
1 main RA artery scallop 3 (10.0)
2 main RA artery scallops 1 (3.3)
RA, Renal artery; SMA, superior mesenteric artery.fenestrated component and distal bifurcated component,and 4 with type II. Two of the 3 proximal type Ia leaks were
treated with repeated ballooning, and one was treated with
the addition of a Palmaz stent (Cordis Endovascular, War-
ren, New Jersey). The patient with a combined type Ia and
III endoleak was treated with repeated ballooning proxi-
mally and at the contralateral leg joint. One of the three
patients with isolated type III endoleaks underwent addi-
tional balloon angioplasty, and two patients underwent
placement of a Palmaz stent. The type III endoleak in one
patient resolved before discharge without any treatment.
Patient follow-up. Two patients were lost to follow-up
at 1month and 10months, and two deaths occurred. Among
the patients eligible for follow-up, 27 of 28 (96.4%) and 23
of 27 (85.2%) underwent follow-up evaluations at 12 and
24 months, respectively.
Death, rupture, conversion, and adverse events. No
deaths occurred 30 days of the procedure. Two late
deaths occurred at 677 and 754 days. One death was a
result of several pre-existing comorbidities and the other
was attributed to atherosclerotic cardiovascular disease, and
an independent Clinical Events Committee (CEC) adjudi-
cated both deaths as not related to the AAA repair.
No aneurysm rupture or conversion to open repair
occurred in the study patients through 24 months of
follow-up, and no AAA-related major adverse events were
observed. Other major adverse events included three epi-
sodes of congestive heart failure in three patients; none
were related to the device or the procedure, as adjudicated
by the CEC. Freedom from major adverse events is de-
picted in Fig 2. The rates of all adverse events are presented
by organ systems in Table VI.
Renal events. Early renal events occurred in two pa-
Fig 2. Kaplan-Meier analysis of freedom from major adverse
events, defined as Q-wave myocardial infarction, congestive heart
failure, cardiac ischemia requiring intervention, renal failure re-
quiring permanent dialysis, bowel obstruction, ischemia or fistula,
stroke, paralysis, conversion to open surgery, aneurysm rupture, or
death. The circles represent time points when any patient is cen-
sored from the analysis. The vertical bars represent 95% confidence
intervals.tients as a result of renal infarcts noted on the predischarge
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serum creatinine levels or other therapy required). Late
renal artery stenosis or occlusion occurred in six of the 57
renal arteries accommodated by fenestrations. Secondary
interventions were performed in five patients with late renal
events.
Late renal artery stenosis was reported in four patients.
One patient was diagnosed with in-stent stenosis of the
right renal artery at 6 months. Review of the predischarge
imaging study revealed suboptimal alignment of the fenes-
tration, possibly due to uneven stent graft expansion as a
result of pre-existing heavy calcifications. This patient was
successfully treated with angioplasty and placement of an
additional 6-  17-mm Express stent (Boston Scientific,
Natick, Mass).
The second patient was diagnosed with bilateral renal
artery in-stent stenoses at 6 months. This patient received
angioplasty of both renal arteries and placement of a
covered iCast stent (Atrium Medical, Hudson, NH) in
Table VI. Number of patients experiencing events by
category
Category No. (%) Comments
Cardiac
0-30 days 2 (6.7) 2 arrhythmia
31-365 days 3 (10.0) 2 CHF, 1 arrhythmia
366 days 1 (3.3) 1 CHF
Renal
0-30 days 2 (6.7) 2 renal infarct
31-365 days 3 (10.0) 1 occlusion, 2 stenosis
366 days 3 (10.0) 1 occlusion, 2 stenosis
Vascular
0-30 days 7 (23.3) 7 transfusions, 1 LE embolusa
31-365 days 0 (0)
366 days 0 (0)
Pulmonary
0-30 days 1 (3.3) 1 supplemental O2 at
discharge
31-365 days 1 (3.3) 1 pneumonia requiring
antibiotics
366 days 0 (0)
Gastrointestinal
0-30 days 1 (3.3) 1 paralytic ileus 4 days
31-365 days 0 (0)
366 days 0 (0)
Neurologic
0-30 days 0 (0)
31-365 days 0 (0)
366 days 0 (0)
Wound
0-30 days 1 (3.3) 1 infection requiring
antibiotics
31-365 days 2 (6.7) 2 incisional hernia
366 days 0 (0)
Other
0-30 days 9 (30.0)
31-365 days 9 (30.0)
366 days 4 (13.3)
CHF, Congestive heart failure; LE, lower extremity.
aTreated with embolectomy. This patient also required transfusion.the left renal artery to treat residual stenosis and dissec-tion. Follow-up examinations at 12 months demon-
strated patent and stenosis-free bilateral renal arteries.
In-stent stenosis of the right renal artery was observed
at 12 months in the third patient. The patient was success-
fully treated with angioplasty and additional stent place-
ment (Palmaz Corinthian stent, Cordis Endovascular, War-
ren, NJ). Follow-up evaluation demonstrated a patent,
stenosis-free right renal artery.
In the fourth patient, in-stent stenosis of the right renal
artery was noted at 24 months. The metallic component of
the 7-  20-mm Paramount stent (eV3, Plymouth, Minn)
was visibly deformed, an event likely resulting from caudal
movement (10 mm) of the proximal fenestrated compo-
nent. The stenosis was successfully treated with the implan-
tation of two additional 7-  17-mm Express stents.
An additional stenosis of a right renal artery in the bare
stent fixation zone was observed in a patient at 40 months
and was treated by angioplasty and stent placement. This
artery was not included in the calculation of renal events
because it was not incorporated by a fenestration.
Renal artery occlusion developed in two patients. The
size of the left kidney had markedly diminished at 6 months
in one patient, and angiography demonstrated an occluded
left renal artery with proximal compression of the left renal
stent. The patient underwent a left iliac-renal bypass that
successfully restored on of blood flow to the left kidney. In
the other patient, the size of the left kidney was slightly
decreased at 6 months, but a renal occlusion was not noted
until the 12-month follow-up. The patient did not receive
any secondary intervention and has maintained a stable
serum creatinine level of 1.3 mg/dL through 24 months of
follow-up.
Endoleak and aneurysm growth. No type I or type
III endoleaks developed through 24 months. Type II en-
doleak was observed in eight of 26 patients (30.8%) before
discharge, in six of 23 (26.1%) at 12 months, and in four of
20 (20.0%) at 24 months. One patient with a persistent
type II endoleak was treated with coil embolization of the
inferior mesenteric artery (IMA) at 8 months, with no type
II endoleak noted on subsequent follow-up evaluations.
No aneurysm enlargement 5 mm was documented.
At 24months, aneurysm shrinkage5mmwas observed in
16 of 23 patients (69.6%), with shrinkage 10 mm ob-
served in 14 (60.9%; Table VII).
Migration and device integrity. One patient re-
quired reintervention for clinically significant graft migra-
tion. Caudal movement (approximately 6 mm) of the prox-
imal fenestrated component was likely responsible for
deformation of the right renal stent, with subsequent renal
stenosis that required a secondary intervention (previously
described). No proximal type I endoleak was identified, and
the aneurysm has decreased in diameter by approximately
15 mm since the implantation of the fenestrated device.
Two device integrity issues were observed. In one
patient, fracture of the left renal artery stent (Express Biliary
LD, Boston Scientific) was observed on 12- and 24-month
CT evaluations. The renal artery has remained patent
through 24 months, with no clinical sequelae. In the other
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trated graft was observed on the 6-month CT evaluation.
Follow-up evaluations at 12 months revealed a patent graft
and bilateral renal arteries in this patient, with no clinical
sequelae.
DISCUSSION
The mortality benefit ascribed to endovascular aortic
repair vs open surgical repair16 has the potential to be more
significant for aneurysms encroaching upon the renal and
visceral branches due to a higher risk of complications
associated with open repair of such aneurysms.16-18 Endo-
vascular grafts with fenestrations can improve proximal
sealing in patients with juxtarenal aneurysms and short
infrarenal aortic necks. However, impediments to the use of
fenestrated devices include technical challenges of device
design and deployment, implant integrity, and the ability of
regional centers to support this technology with adequate
training and resources.
Single-center reports of fenestrated devices9-12,19,20
have demonstrated successful intermediate-term outcomes
that resemble those from large studies of the Zenith infra-
renal device.14,15 In the current multicenter study with
stringent patient selection criteria, no ruptures, conver-
sions, or aneurysm-related deaths occurred through 24
months of follow-up.
The planning and sizing of the Zenith fenestrated graft
is more involved than that of a standard Zenith AAA graft.
It is critical that implanting physicians understand the
requisite imaging and anatomic criteria for the design of
fenestrated devices. Adequate CT imaging studies with
sufficient z-plane (longitudinal) resolution are required to
Table VII. Change in the aneurysm size from
predischarge values
Change over time Total No. (%)
1-month 27
Shrinkage 10 mm 0 (0)
Shrinkage 5 to 10 mm 1 (3.7)
No changea 26 (96.3)
Growth 5 mm 0 (0)
6-month 26
Shrinkage 10 mm 4 (15.4)
Shrinkage 5 to 10 mm 8 (30.8)
No change 14 (53.8)
Growth 5 mm 0 (0)
12-month 24
Shrinkage 10 mm 10 (41.7)
Shrinkage 5 to 10 mm 6 (25.0)
No change 8 (33.3)
Growth 5 mm 0 (0)
24-month 23
Shrinkage 10 mm 14 (60.9)
Shrinkage 5 to 10 mm 2 (8.7)
No change 7 (30.4)
Growth 5 mm 0 (0)
aNo change was defined as an increase or decrease in aneurysm size of
5 mm.obtain accurate anatomic measurements. In addition, theconfiguration of the renal and other visceral vessels must be
reviewed and determined to be amenable to fenestration
alignment. For example, if the vessels are very close to-
gether (roughly 5 mm longitudinal distance and 45°
radially), the design may require fenestrations to overlap or
struts may cross the visceral artery orifice. The main renal
trunk should also be long enough to allow proper place-
ment of a renal stent with the uniform-diameter portion
lying within the renal artery and the flared portion extend-
ing into the aorta.
Procedural techniques did not markedly differ between
sites in this study. The methods to obtain renal access
before complete deployment of the proximal fenestrated
component and the choice of mating stents constituted
most of the differences. We anticipate that the procedural
parameters will improve as each investigator gains more
experience with the fenestrated device.
The presence of aneurysmal disease close to the renal
arteries results in a higher incidence of deleterious renal
outcomes after open surgical repair, where periprocedural
renal events have been largely attributed to ischemia or
emboli created by the requisite proximal dissection and
suprarenal clamping.17 Endovascular repair avoids these
risks of surgical repair, but the manipulation required may
also dislodge atheroma, with resultant renal infarcts. The
required manipulation is more significant in patients with
concomitant renal stenosis.
In addition, endovascular procedures require the use of
potentially nephrotoxic contrast agents. When these are
superimposed on preoperative renal insufficiency, the abil-
ity of the kidneys to recover from the procedure is ham-
pered. These observations have been reported previously21
and resulted in the exclusion of patients with significant
renal stenoses (50%) or with serum creatinine levels 2
mg/dL. Renal infarcts were noted on the predischarge CT
scans (both reperfused during follow-up) in two patients,
and both had atheroma within the proximal neck. There-
fore, investigators are strongly encouraged to assess all
available preprocedural imaging for the presence of ather-
oma at the orifice of the renal arteries.
Late renal events are perhaps more concerning than
early events. Events occurring after 1 month are largely
related to stenosis or occlusion of the renal vasculature. A
study by Haddad et al21 found renal obstructions in 15 of
142 renal arteries accommodated by fenestrations, irrespec-
tive of preoperative renal stenosis. In the current study, late
renal events occurred in six of 57 renal arteries accommo-
dated by fenestrations (54 of them stented). Of these, two
cases exemplify possible causes for renal artery stenosis or
occlusion.
A retrospective review in one patient with renal artery
occlusion revealed suboptimal deployment of the renal
stent into the middle/upper portion of the fenestration.
Even slight distal migration of the fenestrated graft in this
situation can cause proximal compression of the renal stent.
We therefore recommend that after sheath access into the
renal vessels but before removal of the constraining wire,
the device be advanced, if necessary, to ensure deployment
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In one patient with renal artery stenosis, a proximal neck
dilation of approximately 4 mm was observed, which may
have contributed to the slight caudal migration of the graft,
thus causing compression and even deformation of the
renal stent. Additional stenting was performed in this case,
but we remain concerned that migration may persist.
As previously reported, this situationmay be avoided by
placing the graft more proximally into a healthy aortic
segment.21 This may require the incorporation of both the
SMA and celiac vessels, however, thus further complicating
the procedure. Accurate planning and sizing of the device
and optimized device deployment are important for mini-
mizing the risk of late renal events. In addition, this study
emphasizes the importance of continued and careful assess-
ment of renal artery flow to detect and treat adverse renal
events in a timely manner.
The stability of the proximal component is paramount
to long-term success of the fenestrated device, because even
slight graft movement (less than the migration standard of
10 mm) can be catastrophic to the visceral arteries accom-
modated by fenestrations. The Zenith fenestrated device
uses the same barb fixation that has adequately stabilized
the conventional infrarenal Zenith device through 5 years
of follow-up.22 The fenestrated device has a modular de-
sign that allows for relative movement of the proximal
fenestrated component and distal bifurcated component.23
Thus, forces causing migration are not directly transmitted
from one component to the other. In addition, the two
components can adjust independently to morphologic
changes by relative movement, thus diminishing the risk of
aneurysm repressurization. To maintain complete seal
when such relative movement occurs, we recommend that
the two components overlap by at least two stents. Long
proximal components are ideal, terminating approximately
20 mm above the aortic bifurcation; the distal component
is intended to be deployed with the distal end of the
contralateral limb approximately 5 to 10 mm above the
aortic bifurcation. As for other device integrity issues,
the current study only noted a renal stent fracture and a
single barb separation; both were free of any clinical
sequelae.
CONCLUSIONS
This article presents the intermediate results of a
prospective multicenter study designed to evaluate the
preliminary safety and effectiveness of the Zenith Fenes-
trated Endovascular Graft. The results through 2 years of
follow-up resemble those of single-center reports on fenes-
trated devices. The results of this study are also similar to
those of the parent infrarenal Zenith endograft with respect
to protection from rupture, freedom from migration, and
other endovascular end points. Continued emphasis must
be placed on training the implanting centers on patient
selection, device design, and the evolution of implantation
techniques.We thank Lori Nolte, PhD, andQing Zhou, PhD, from
MED Institute Inc, for their assistance with manuscript
preparation.
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hepatic artery next to the superior mesenteric artery that needed to be
accommodated with a fenestration.
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October 2009737.e1 Greenberg et alTable III (online only). Reasons for not including 19
patients who passed the initial enrollment screening in
the study
Reasons No. (%)
Aneurysm diameter 5.0 mm 1 (5.3)
Proximal neck length 4 mm 4 (21.1)
Proximal neck length 15 mm 2 (10.5)
Proximal neck angulation relative to long axis of
aneurysm 45° and/or immediate suprarenal
neck angulation relative to immediate
infrarenal neck 45° 2 (10.5)
Nonbifurcated segment of any artery to be
stented 15 mm in length 1 (5.3)
Unsuitable arterial anatomya 8 (42.1)
Baseline creatinine 2.0 mg/dL 1 (5.3)
aUnsuitable arterial anatomy included significant tortuosity and/or calcifi-
cation of the iliac arteries, presence of two main renal arteries on the same
side, presence of excessive thrombus in the perirenal aorta, or presence of a
